Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions (Tables)

v3.21.1
Composition of Certain Financial Statement Captions (Tables)
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Composition of Certain Financial Statement Captions
(In thousands) March 31,
2021
December 31,
2020
Accounts receivable, net:
Accounts receivable $ 322,940  $ 288,369 
Less: allowance for credit losses (2,478) (2,055)
$ 320,462  $ 286,314 
Inventories, net:
Consumable supplies $ 114,042  $ 86,779 
Finished products 39,287  36,831 
Work in-process 4,706  5,268 
Raw materials 5,966  5,784 
Less: inventory reserve (4,897) (2,321)
$ 159,104  $ 132,341 
Other current assets and prepaid expenses:
Taxes recoverable $ 9,480  $ 13,440 
Prepaid expenses 13,628  7,259 
Prepaid insurance 1,458  3,803 
Other receivables 351  2,502 
Other 5,063  5,309 
$ 29,980  $ 32,313 
Intangible assets, net:
Customer relationships $ 447,095  $ 448,751 
Technologies 288,222  296,623 
Trade names 49,805  49,820 
Covenants not to compete 16,326  16,334 
Licenses 5,766  5,766 
Product registrations 7,881  8,025 
Other 6,288  6,513 
Less: accumulated amortization (365,074) (356,830)
$ 456,309  $ 475,002 
Accrued expenses:
Inventory received but not invoiced $ 50,732  $ 72,160 
Commitments and contingencies 17,777  15,454 
Employee benefits 46,428  43,300 
Contract liabilities 15,031  15,783 
Clinical trials 6,597  7,112 
Contingent consideration —  1,188 
Finance leases short-term 2,287  2,453 
Professional fees 4,790  4,985 
Other 69,477  78,434 
$ 213,119  $ 240,869 
(In thousands) March 31,
2021
December 31,
2020
Other long-term liabilities:
Contingent consideration $ 3,564  $ 4,507 
Mortgages and other debts payable 3,325  3,837 
Finance leases long-term 2,506  2,805 
Contract liabilities 557  595 
Other 16,759  25,328 
$ 26,711  $ 37,072 
Changes in Goodwill
The following table summarizes the changes in Goodwill by reporting unit during the three months ended March 31, 2021.
2021
(In thousands) Gross goodwill at January 1 Cumulative impairment at January 1 Goodwill impairment Foreign exchange and other Balance at March 31
Pharmaceuticals
CURNA $ 4,827  $ (4,827) $ —  $ —  $ — 
Rayaldee 93,418  —  —  (3,998) 89,420 
FineTech 11,698  (11,698) —  —  — 
OPKO Biologics 139,784  —  —  —  139,784 
OPKO Chile 4,505  —  —  (88) 4,417 
OPKO Health Europe 8,086  —  —  (354) 7,732 
OPKO Mexico 100  (100) —  —  — 
Transition Therapeutics 3,421  (3,421) —  —  — 
Diagnostics
BioReference 434,809  —  —  —  434,809 
OPKO Diagnostics 17,977  (17,977) —  —  — 
$ 718,625  $ (38,023) $ —  $ (4,440) $ 676,162